Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Notable Analyst Rating Changes 07/10: (LUV) (BMR) (CE) Upgraded; (FST) (LPX) (TSN) Downgraded
-
Cantor Fitzgerald Downgrades DuPont Fabros Technology (DFT) to Hold; Less Data Needed
-
Cantor Fitzgerald Upgrades BioMed Realty (BMR) to Buy; Growing Demand...For Labs
-
Cantor Fitzgerald Starts Las Vegas Sands (LVS) at Buy; Dominant Global Player with Significant Assets
-
Cantor Fitzgerald Starts MGM Resorts (MGM) at Buy; Continued Deleveraging; Las Vegas Bouncing Back
-
Cantor Fitzgerald Starts Wynn Resorts (WYNN) at Buy; Recent Correction Offers Good Entry Point
-
Analyst Says Obagi (OMPI) Could Soon See Offers from 'Multiple Suitors'
-
Cantor Fitzgerald Downgrades Cousins Properties (CUZ) to Sell; Look For Better Entry Point
-
Cantor Fitzgerald Upgrades UDR, Inc. (UDR) to Hold; Redefined its Footprint
-
Notable Analyst Rating Changes 06/28: (OREX) (HAL) (DRIV) Upgraded; (WFT) (MTL) (CBE) Downgraded
-
Cantor Fitzgerald Starts Broadcom (BRCM) at Buy; Everything Goes Through Me First
-
Cantor Fitzgerald Starts Qualcomm (QCOM) at Buy; The Dominator
-
Cantor Fitzgerald Starts Fluidigm Corporation (FLDM) at Buy; Taking on The Competition, One Cell At a Time
-
Cantor Fitzgerald Starts Accelrys (ACCL) at Buy; Scientific R&D Enhanced with Software
-
Cantor Fitzgerald Starts Xyratex (XRTX) at Hold; Bumpy Road Ahead
-
Cantor Fitzgerald Starts Zimmer Holdings (ZMH) at Hold; Secular Play
-
Cantor Fitzgerald Starts Stryker (SYK) at Hold; M&A Strategy Strong, But Waiting For Better Entry
-
Cantor Fitzgerald Cuts Rating and Price Target Ventrus Biosciences (VTUS); Phase III Trial Misses; New Exit Strategy Potential Sale
-
Cantor Fitzgerald Maintains a 'Buy' on Celgene (CELG); Cutting Numbers After European Application Withdrawn
-
Cantor Fitzgerald Starts Health Net (HNT) at Hold; Several Drivers Into 2013, But...
-
Cantor Fitzgerald Starts Aetna (AET) at Hold; Concentration in Lumpy National Accounts Market
-
Cantor Fitzgerald Starts WellPoint (WLP) at Hold; Business Mixed, Waiting on Better Numbers
-
Cantor Fitzgerald Starts Whole Foods Market (WFM) at Buy; Everything Just Looks Right
-
Cantor Fitzgerald Starts UnitedHealth Group (UNH) at Buy; Expecting The Best EPS Growth in 2012-13
-
Cantor Fitzgerald Starts Humana (HUM) at Buy; Medicare Is A Large Opportunity
-
Cantor Fitzgerald Upgrades China Telecom (CHA) to Hold; Priced Right
-
Cantor Fitzgerald Starts Immunogen Inc. (IMGN) at Hold, $15 Target
-
Q1 Preview: Analysts Moderate on Kroger (KR) Into Results; Fuel, Inflation are Headwinds
-
Cantor Fitzgerald Reiterates a 'Buy' on Microsemi (MSCC); Confidence Bolstered After Meeting with Management
-
Cantor Fitzgerald Downgrades Centene (CNC) to Hold; Shortfall Is A Big Psychological Blow To Medicaid Names
-
Notable Analyst Rating Changes 06/11: (EMC) (PGN) (SKX) Upgraded; (AKS) (PGR) (AEM) Downgraded
-
Cantor Fitzgerald Upgrades Brocade (BRCD) to Buy; Improving Balance Sheet & Market Share Gains
-
Cantor Fitzgerald Upgrades EMC (EMC) to Buy; Predictable, High Quality Recurring Revenue
-
Cantor Fitzgerald Upgrades NetApp (NTAP) to Buy; Compelling Risk Reward After Reset
-
Notable 52-Week Highs and Lows of the Day 06/08: (SGEN) (NEON) (DG) High; (ANR) (ACI) (AUO) Low
-
Cantor Fitzgerald Maintains a 'Hold' on Kroger (KR); Cutting Estimates Ahead of Q1 Report
-
Cantor Fitzgerald Starts Cypress Semi (CY) at Sell; Competition May Ruin the Touch-SoC Party
-
Cantor Fitzgerald Starts Ligand Pharma (LGND) at Buy; Fundamentally Undervalued; Building Momentum In 2012
-
Cantor Fitzgerald Starts Neonode (NEON) at Buy; Expecting Tier-One Wins For Printers and Handsets
-
Cantor Fitzgerald Maintains a 'Sell' on United Natural Foods (UNFI); Operating Cash Flow Appears Insufficient
-
Cantor Fitzgerald Raises PT and Estimates on NewLink Genetics (NLNK); Great Data at ASCO
-
Cantor Fitzgerald Upgrades Equity LifeStyle Properties (ELS) to Buy; Starting To Look Like A Bargain
-
Cantor Fitzgerald Maintains a 'Buy' on Obagi Medical Products (OMPI); Volatility Expected Around Shareholder Meeting
-
Cantor Fitzgerald Reiterates a 'Buy' on Sirona Dental (SIRO); Discounted Valuation Fails to Account for Vast Underpenetration Worldwide
-
Notable Analyst Rating Changes 06/04: (BAC) (ABMD) (STI) Upgraded; (RF) (SCHW) (HOT) Downgraded
-
Cantor Fitzgerald Starts Galena Biopharma (GALE) at Buy; New Approach to Breast Cancer
-
Post Properties (PPS) Files To Sell Up to 4M Shares
-
Cantor Fitzgerald Starts Cross Country Healthcare (CCRN) at Buy; Improved Fundamentals
-
Canaccord Genuity Morning Coffee on JP Morgan (JPM): Look Out Below!
-
Cantor Fitzgerald Starts Align Technology (ALGN) at Buy, $37 Price Target

